BAXDELA® (POWDER)

Drug Information Related Patent
Hold Company
MELINTA
Learn More
Dosage and Administration
POWDER;INTRAVENOUS
Specification
EQ 300MG BASE/VIAL
Indication
BAXDELA® is used for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia.
Use
Instructions for Use
API
DELAFLOXACIN MEGLUMINE
API Structure
We Supply
DELAFLOXACIN MEGLUMINE
Note:

In-house Standard
Facility GMP

null
Note:

null

null
Note:

null

Drug Patent
Patent NoExpiration Date
76357732029/3/13
77281432031/6/19
82528132026/10/2
82738922026/8/6
84100772029/3/13
86480932025/10/7
88719382029/9/23
92000882029/3/13
94935822033/2/27
95392502025/10/7
97508222029/3/13
RE466172029/12/28
84973782029/12/28
API Patent
Patent NoExpiration Date
82528132026/10/2
82738922026/8/6
86480932025/10/7
95392502025/10/7
HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen-ING. All Rights Reserved.
dcat
Member of
dcat
Top